Mark Marmur News Today

Amarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call Transcript May 1, 2024 Amarin Corporation plc misses on earnings expectations. Reported EPS is $-0.01 EPS, expectations were $-0.0075. AMRN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome […]

AMRN earnings call for the period ending March 31, 2024.

Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect PatientsDUBLIN, Ireland and...

Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of ActionDUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2024 -- Amarin Corporation plc today highlighted three data...

-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp, LDL-C Levels -- -- Lp Results Published Simultaneously in the Journal of the American...

DUBLIN, Ireland and BRIDGEWATER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company received a Decision to Grant from the European Patent Office

-- Company Delivers Total Revenues of $75 Million in the Fourth Quarter and $306 Million for the Full-Year 2023 ---- Reaffirms Year-End 2023 Cash Position of $321 Million and Full-Year Positive Cash Flow of $10 Million -- -- Company Reports Fourth Quarter 2023 Total Operating Expense of $50 Million ---- Initiated Shareholder Approval Process to Execute a Share Repurchase Program of up to $50 Million by the End of the Second Quarter 2024 ---- Company to Host Conference Call Today at 8:00 a.m. EDT

Full-Year 2023 Earnings Reveal Challenges and Strategic Focus on Cash Flow

AMRN earnings call for the period ending December 31, 2023.

AMRN earnings call for the period ending December 31, 2023.